Comparative Pharmacology
Head-to-head clinical analysis: BENYLIN versus ZADITOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENYLIN versus ZADITOR.
BENYLIN vs ZADITOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BENYLIN (diphenhydramine) is a first-generation antihistamine that competitively antagonizes histamine at H1 receptors, thereby alleviating allergic symptoms. It also crosses the blood-brain barrier and acts as a central nervous system depressant via inhibition of histamine and acetylcholine, producing sedative, antiemetic, and antitussive effects.
Selective histamine H1 receptor antagonist. Stabilizes mast cells, reducing release of histamine and other mediators of allergic response.
Oral: 10-20 mL (25-50 mg diphenhydramine) every 4-6 hours; maximum 100 mg per day.
1 drop in each affected eye twice daily, approximately 6-8 hours apart.
None Documented
None Documented
Terminal elimination half-life: 4-6 hours in adults; extended to 10-12 hours in hepatic impairment, increasing risk of accumulation.
Terminal elimination half-life is approximately 7 hours in adults, which supports twice-daily dosing for sustained ocular effects.
Renal: ~80% as unchanged drug and glucuronide conjugates; fecal/biliary: ~20%.
Primarily renal excretion as unchanged drug (approximately 30-40% of dose) and biliary/fecal elimination of metabolites (60-70%).
Category C
Category C
Antihistamine
Antihistamine